Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm, MIT, Alnylam, UK Patent Office

Premium
Intradigm Licenses Nucleic Acid Delivery IP from MIT
 
Intradigm said this week that it has licensed rights to a nucleic acid delivery patent from the Massachusetts Institute of Technology for use in RNAi drug development.
 
The company said the IP it has licensed covers a broad range of biodegradable polymer structures that are used in delivering RNAi-based therapeutics. It added that the license would enable it to pursue applications for its NanoPlex delivery technology across a broader range of therapeutic indications.
 
Intradigm’s RNAi Nanoplex technology is made of an active siRNA molecule and a biodegradable polycationic polymer.
 
Financial terms of the agreement were not released.
 

 
Alnylam Issued UK Patent on siRNA Composition, Methods
 
Alnylam Pharmaceuticals this week announced that it has received a patent from the United Kingdom Patent Office covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs.
 
The patent, No. UK 2417727, is entitled "Double-stranded Ribonucleic Acid with Increased Effectiveness in an Organism." The company said the IP specifically claims siRNA molecules of any length that contain overhangs and blunt ends, including siRNAs containing chemical modifications and certain novel motifs.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.